Revvity, Inc. Common Stock

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines. In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. An associated goal was to have more financial flexibility moving forward. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY.

RVTY

Financials

Revvity, Inc. Common Stock

Haberler

Is Danaher Stock Underperforming the S&P 500?

Revvity Stock: Analyst Estimates & Ratings

RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

Stifel, Revvity hissesi için hedef fiyatı düşürdü

S&P 500 and Nasdaq 100 Post Record Highs on Tech Strength

Revvity hisseleri ilk çeyrek kar tahminlerini aştı

Tech Stock Strength Lifts the Nasdaq 100 to a Record High

RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution

Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics

Revvity’nin 1Ç 2026 sonuçları beklentileri aştı

Revvity (RVTY) Q1 Earnings and Revenues Top Estimates

Revvity kazançları odakta, analistler gelir artışını izliyor